This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ATP13A2 | |
|---|---|
| Name | ATP13A2 |
| Uniprot | Q9NRX5 |
| Organism | Homo sapiens |
| Length | 1180 aa |
| Family | P-type ATPase |
ATP13A2 is a lysosomal P-type ATPase implicated in cation transport and cellular proteostasis. It was first linked to hereditary forms of early-onset parkinsonism and has since been connected to broader neurodegenerative syndromes, lysosomal storage disorders, and metal ion homeostasis. Research on ATP13A2 intersects with studies of Parkinson disease, frontotemporal dementia, amyotrophic lateral sclerosis, and neuronal ceroid lipofuscinosis through shared pathways involving lysosomes, mitochondria, and autophagy.
The protein is a large transmembrane ATPase belonging to the P5B subfamily of P-type ATPases, sharing structural features with other P-type ATPase members such as catalytic phosphorylation (P) domains, actuator (A) domains, and nucleotide-binding (N) domains. Cryo-electron microscopy and X-ray crystallography studies drawing methodological parallels to analyses of Na+/K+-ATPase, SERCA, and H+-ATPase have informed models of transmembrane helix arrangement and conformational cycles. Functional assays relate ATP hydrolysis by ATP13A2 to cation translocation across the lysosomal membrane, coupling ATP-binding from the ATP-binding cassette paradigm to ion movement reminiscent of transporters studied in Saccharomyces cerevisiae and Escherichia coli.
ATP13A2 is predominantly localized to late endosomes and lysosomes, paralleling trafficking patterns characterized for lysosomal proteins like LAMP1, cathepsin D, and NPC1. Expression analyses reveal high abundance in the substantia nigra pars compacta and hippocampus, aligning with tissues examined in studies of Parkinson's disease, Alzheimer's disease, and Huntington's disease. Developmental and cell-type–specific expression maps using techniques comparable to single-cell RNA-seq studies from the Allen Institute for Brain Science and datasets from the Human Protein Atlas show neuronal enrichment and variable expression in astrocytes and oligodendrocytes, echoing patterns documented for MAPT and SNCA.
Biochemical and electrophysiological evidence suggest ATP13A2 transports polyamines, manganese, or other divalent cations, a conclusion informed by comparative studies of metal transporters such as SLC30A10, DMT1, and ZIP8. Mutagenesis of conserved residues in transmembrane segments and phosphorylation motifs alters nucleotide affinity and transport kinetics, similar to observations in SERCA and Na+/K+-ATPase research. Lipid–protein interactions with phosphatidylinositol species and cardiolipin influence ATP13A2 activity, paralleling regulatory mechanisms elucidated for V-ATPase and ATP6V0A1. Cross-talk with autophagic machinery involves proteins like LC3, p62/SQSTM1, and chaperones such as HSP70.
Pathogenic loss of ATP13A2 function produces lysosomal dysfunction, impaired autophagy, and mitochondrial deficits that phenocopy cellular features observed in Parkinson's disease, Lewy body dementia, and Kufor–Rakeb syndrome cohorts. Cellular accumulation of alpha-synuclein inclusions and altered metal homeostasis recapitulate aspects seen in studies of SNCA aggregation and manganese neurotoxicity reported in occupational medicine literature and Minamata disease analyses. Clinical-pathological correlations draw from neuropathological frameworks established for Braak staging, CERAD, and clinicopathologic reports from movement-disorder centers including those associated with Mayo Clinic and Johns Hopkins Hospital.
Biallelic mutations in ATP13A2 cause autosomal recessive parkinsonism in families first described in linkage studies using approaches similar to those employed in mapping genes like LRRK2 and PARKIN. Reported variants include frameshifts, nonsense, missense, and splice-site changes that disrupt ATP-binding or transmembrane integrity; genotype–phenotype correlations reference case series reported in neurologic genetics consortia and gene databases modeled after resources like ClinVar and OMIM. Population genetics analyses using cohorts from the 1000 Genomes Project, gnomAD, and large biobanks such as UK Biobank have characterized allele frequencies and informed pathogenicity criteria akin to guidelines from the American College of Medical Genetics and Genomics.
Model systems used to study ATP13A2 include yeast complementation assays in Saccharomyces cerevisiae, RNAi and gene-editing screens in Drosophila melanogaster, zebrafish studies in Danio rerio, and rodent knockout models in mice generated with techniques paralleling those used for SNCA and LRRK2 models. Cellular models include patient-derived induced pluripotent stem cells and dopaminergic neurons differentiated using protocols informed by groups like the Allen Institute and academic centers such as Broad Institute and Salk Institute. Phenotypes replicated across models include age-dependent neurodegeneration, altered metal sensitivity, and defective autophagic flux, findings published in journals that often cite work from Nature, Science, and Cell.
Therapeutic strategies target restoration of lysosomal function, metal chelation, modulation of autophagy, and enhancement of proteostasis using small molecules, gene therapy, and pharmacologic chaperones—approaches analogous to interventions tested for GBA-related Parkinsonism, LRRK2 inhibitors, and antisense oligonucleotides developed for SMN1. Drug-repurposing screens leveraging chemical libraries used by consortia such as the NIH and European Molecular Biology Laboratory have nominated candidates that modulate ATP13A2-related pathways. Clinical implications emphasize genetic testing in early-onset parkinsonism cohorts studied at movement-disorder centers including Mayo Clinic and UCLA, and incorporation of ATP13A2 status into biomarker studies coordinated by initiatives like AMP-PD.
Category:Human proteins